Join to View Full Profile
333 Cedar StYale University School Of MedicineNew Haven, CT 06510
Phone+1 203-200-4822
Fax+1 203-200-2099
Dr. Hurwitz is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2000 - 2004
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1998 - 2000
Weill Cornell MedicineClass of 1998
Certifications & Licensure
CT State Medical License 2010 - 2025
MA State Medical License 2000 - 2010
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes Start of enrollment: 2018 Feb 06
- Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer Start of enrollment: 2019 Dec 23
Roles: Contact, Principal Investigator
- A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer Start of enrollment: 2018 Jun 19
Roles: Contact
- Join now to see all
Publications & Presentations
PubMed
- Presence of tertiary lymphoid structures and exhausted tissue-resident T cells determines clinical response to PD-1 blockade in renal cell carcinoma.Miya B Hugaboom, Lena V Wirth, Kelly Street, Neil Ruthen, Opeyemi A Jegede
Cancer Discovery. 2025-02-24 - Sorafenib or anthracycline-based chemotherapy for progressive desmoid tumors.Philippos Apolinario Costa, Arshia Arora, Yannelys Fernandez, Irvin Yi, Baylee Bakkila
Cancer. 2025-01-01 - 1 citationsCost trends of metastatic renal cell carcinoma therapy: the impact of oral anticancer agents and immunotherapy.Rebecca Forman, Jessica B Long, Sarah J Westvold, Khushi Agnish, Hannah D Mcmanus
JNCI Cancer Spectrum. 2024-09-02
Press Mentions
CAR T Cell Therapy May Eliminate Tumor Cells Missed by SurgeryFebruary 9th, 2023
Clinical Data from Phase 1 Dose-Escalation Study of Single-Agent NKTR-214 in Patients with Renal Cell Carcinoma Presented at the ASCO 2017 Genitourinary Cancers SymposiumFebruary 19th, 2017- 'We're Not There yet': CAR T-cell Therapy for Renal Cell CarcinomaNovember 17th, 2023
Grant Support
- Enhancing Melanoma TIL Efficacy with Multifactor mRNA-Mediated T Cell ReprogrammingYALE UNIVERSITY2023–2025
- Enhancing Melanoma TIL Efficacy with Multifactor mRNA-Mediated T Cell ReprogrammingYALE UNIVERSITY2023–2025
- Screening Of Synthetic Lethality With C. Elegans RBNational Cancer Institute2004–2008
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
